International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-1 doi: 10.5281/zenodo.14211008
Original Research Article
Comparison of Clinical Effects of Hyperbaric Ropivacaine and Hyperbaric Ropivacaine with Dexmedetomidine for Spinal Anesthesia in Elective Lower Limb Orthopedic Procedures
Published
Feb. 4, 2025
Abstract

This study aimed to compare the clinical effects of hyperbaric ropivacaine alone and in combination with dexmedetomidine for spinal anesthesia in elective lower limb orthopedic procedures. A prospective, randomized, double-blind study was conducted on 100 patients undergoing elective lower limb orthopedic surgeries. Patients were randomly allocated into two groups: Group R received hyperbaric ropivacaine 0.75% (3 mL)+0.5 ml normal saline(total volume 3.5ml), and Group RD received hyperbaric ropivacaine 0.75% (3 mL) with dexmedetomidine (10μg) (total volume 3.5ml). The onset and duration of sensory and motor block, hemodynamic parameters, time to first analgesic request, and side effects were recorded. Results showed that the addition of dexmedetomidine to hyperbaric ropivacaine significantly prolonged the duration of sensory and motor block (p < 0.001), extended the time to first analgesic request (p < 0.001), and provided better intraoperative conditions compared to ropivacaine alone. Hemodynamic parameters remained stable in both groups, with no significant differences in side effects. This study concludes that the addition of dexmedetomidine to hyperbaric ropivacaine for spinal anesthesia in lower limb orthopedic procedures provides superior analgesia and prolonged motor and sensory block without significant hemodynamic alterations or increased side effects.

Recommended Articles
Loading Image...
Volume-6, Issue-1
Citations
1683 Views
86 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved